Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women

Plain-language summary

Published 2022 in Sci Rep, this work by Fukamizu Y and collaborators tackles a specific question within safety-focused NMN/NAD+ research.

Key findings reported by the authors

• Human safety evaluation of oral NMN administration in healthy adult men and women (Sci Rep, 2022)
• Reported NMN was generally well-tolerated in the doses and duration studied
• Adds short-term tolerability data in humans rather than animal-model mechanism

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to safety decisions, with secondary relevance to dosage and science. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.